TCR gene-engineered T cell: limited T cell activation and combined use of IL-15 and IL-21 ensure minimal differentiation and maximal antigen-specificity.
Pouw
Nadine
N
Laboratory of Experimental Tumor Immunology, Dept Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
Treffers-Westerlaken
Elike
E
Mondino
Anna
A
Lamers
Cor
C
Debets
Reno
R
D000818:Animals; D018106:CD28 Antigens / Q000276:immunology; D017252:CD3 Complex / Q000276:immunology; D002454:Cell Differentiation; D002478:Cells, Cultured; D003602:Cytotoxicity, Immunologic; D018984:Epitopes, T-Lymphocyte / Q000276:immunology*; D006801:Humans; D007113:Immunity, Innate; D007156:Immunologic Memory; D007371:Interferon-gamma / Q000096:biosynthesis / Q000276:immunology; D019409:Interleukin-15 / Q000276:immunology*; D007378:Interleukins / Q000276:immunology*; D008213:Lymphocyte Activation; D051379:Mice; D008810:Mice, Inbred C57BL; D015202:Protein Engineering; D011948:Receptors, Antigen, T-Cell / Q000235:genetics / Q000276:immunology*; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology*; D000098546:Interleukin-21
D018106:CD28 Antigens; D017252:CD3 Complex; D018984:Epitopes, T-Lymphocyte; D019409:Interleukin-15; D007378:Interleukins; D011948:Receptors, Antigen, T-Cell; D007371:Interferon-gamma; D000098546:Interleukin-21